Mekinist

Trametinib, the active ingredient in Mekinist, is a MEK inhibitor presented as a 2 mg oral tablet for oral use. It treats BRAF V600E/K mutation‑positive unresectable or metastatic melanoma and, in combination, KRAS G12C‑mutated non‑small cell lung cancer and anaplastic thyroid cancer.

GNH USA supplies Mekinist as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring timely delivery to treatment sites and compliance with local regulations.

Mekinist (trametinib) targets the MAPK/ERK signaling pathway and is indicated for specific mutation‑driven cancers.

- BRAF V600E/K mutation‑positive melanoma: Improves progression‑free and overall survival in patients with unresectable or metastatic disease. - KRAS G12C‑mutated non‑small cell lung cancer (in combination therapy): Contributes to tumor response when used with a KRAS inhibitor. - Anaplastic thyroid cancer (in combination therapy): Enhances disease control as part of a multi‑agent regimen.

Trametinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: frequent watery stools, often mild to moderate. - Rash: maculopapular skin eruptions. - Nausea: feeling of sickness, may be intermittent. - Fatigue: reduced energy levels and tiredness. - Peripheral edema: swelling of extremities. - Elevated liver enzymes: increased ALT/AST.

Serious or Rare Side Effects: - Cardiac dysfunction: reduced left ventricular ejection fraction or heart failure. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Hepatotoxicity: severe liver injury with jaundice. - Hemorrhagic events: increased risk of bleeding.

When prescribing trametinib, clinicians should consider several safety precautions to minimise risk.

- Baseline cardiac assessment: perform echocardiogram to evaluate left ventricular function before starting therapy. - Dermatologic monitoring: inspect skin regularly for rash or severe reactions. - Liver function tests: check ALT/AST levels periodically during treatment. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risks; discuss contraception. - Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. - Store at ambient temperature: keep tablets below 25 °C in original container, protect from moisture and light.

Trametinib may affect or be affected by other medicines; awareness of key interactions helps ensure safe use.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce trametinib exposure, compromising efficacy. - Concomitant use with other MEK or BRAF inhibitors: increases risk of severe toxicities and is generally contraindicated.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise trametinib plasma levels, requiring dose adjustment. - Anticoagulants (e.g., warfarin): may have altered anticoagulant effect; monitor INR closely. - QT‑prolonging agents: combined use may increase risk of cardiac arrhythmias; perform ECG monitoring.